Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has disclosed Other Non-Current Liabilities across 13 years of filings, most recently posting $1.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $1.1 million, down 6.92% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 million (down 6.92% YoY), and the FY2025 annual result was $1.1 million, down 7.1% from the prior year.
• Other Non-Current Liabilities came in at $1.1 million for Q1 2026 at Rocket Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $2.9 million in Q4 2023 to a low of $37000.0 in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $1.1 million (2024), against an average of $1.3 million.
• Across the five-year window, Other Non-Current Liabilities jumped 4951.35% in 2023 and sank 61.14% in 2024, its largest moves.
• Rocket Pharmaceuticals' Other Non-Current Liabilities stood at $2.6 million in 2022, then climbed by 13.14% to $2.9 million in 2023, then tumbled by 61.14% to $1.1 million in 2024, then retreated by 7.1% to $1.1 million in 2025, then grew by 0.19% to $1.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $1.1 million (Q1 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.